禽类Ii基因的克隆、表达及其功能的初步研究
|
摘要
Ii链是一种非多态性的Ⅱ型跨膜蛋白，在调节MHC Ⅱ类分子的表达和功能方面发挥重要作用。人类和小鼠的Ii基因都是单拷贝基因，其mRNA都能够以不同的拼接模式产生不同形式的Ii链异构体。但是禽类Ii链是否存在异构体还未见报道。我们利用RT-PCR和RACE的方法确定了两个鸡Ii链cDNA，并且用Southern blotting、Northern blotting和免疫荧光法分别检测了Ii基因的拷贝数、mRNA表达和蛋白表达情况。被命名为鸡Ii-1的cDNA长为1，151bp，含有一个由672bp组成的开放阅读框，它与一个已经被报道的鸡Ii链序列相一致；另一个Ii链cDNA被命名为鸡Ii-2，其大小为1，337bp，含有一个由861bp组成的开放阅读框。Ii-1与Ii-2在核苷酸和氨基酸水平上的同源性均为99％，两者的区别在于Ii-2比Ii-1多出一个Tg区。Southern blotting结果表明，这两个cDNA由一个单拷贝的基因产生。Northern blotting结果表明，Ii-1和Ii-2在6周龄鸡的脾脏和法氏囊中高表达，而在胸腺、心脏和肝脏中有Ii-1低水平表达，但未检测到Ii-2的表达；在鸡胚胎的晚期发育中，两种Ii链异构体在脾脏和法氏囊中均被检测到高水平表达。脾组织切片的免疫荧光染色结果表明，Ii链主要表达在细胞膜上。这些资料表明，鸡Ii链存在两种异构体，它们由mRNA的选择性拼接产生，并且主要在免疫器官中高表达。
利用一对自行设计的简并引物，通过RT-PCR和RACE方法，我们获得了鸭Ii链cDNA，并将其命名为鸭Ii-1。Ii-1长为1，190bp，含有一个41bp的5′不翻译区、一个669bp的开放阅读框和一个480bp的3′不翻译区。鸭Ii链也存在编码含有Tg区的异构体，我们将其命名为鸭Ii-2。鸭Ii-1与鸡Ii-1氨基酸序列的同源性为82％，与哺乳动物Ii P31／P33之间的同源性约为60％。鸭Ii-2 Tg区与鸡Ii-2Tg区在氨基酸水平上的相似性高达96％，与哺乳动物Ii链Tg区之间也达到70％。利用一对能同时扩增鸭Ii链两种异构体的引物，通过半定量RT-PCR检测不同组织Ii mRNA的分布情况，结果表明，Ii链两种异构体在不同组织中广泛表达，尤其在脾脏和法氏囊中高水平表达。应用comparative protein modeling分析了鸭Ii链三聚体区和Tg区的三维结构，它们与人Ii链相应domain的结构完全相似。这些结果表明鸭Ii链也存在两种异构体，它们主要在免疫器官中高表达，并且
The invariant chain (Ii) is a non-polymorphic type II transmembrane protein and plays a central role in regulating the expression and function of class II major histocompatibility complex (MHC) molecules. The biosynthesis of distinct forms of the invariant chain (Ii) protein from a unique gene as the result of differential splicing patterns has been observed in humans and mice. However, there have been no reports on the existence of Ii isoforms in avian species. In the present study, we identified two chicken Ii cDNAs by RT-PCR and RACE, and examined the Ii gene copy number, mRNA expression and protein expression by Southern blotting, Northern blotting and immunofluorescence confocal microscopy, respectively. One of the Ii cDNAs, named Ii-1, was 1,151 bp in length, and had an open reading frame (ORF) of 672 nucleotides, in agreement with a previously identified chicken Ii sequence; the other, named Ii-2, was 1,337 bp long and had an ORF of 861 nucleotides. The Ii-1 and Ii-2 isoforms are similar to each other where they overlap, and the sequence similarity between them is 99% at either the nucleotide or amino acid level. However, they differ in the presence or absence of a Tg domain. Southern blotting confirmed that these cDNAs were derived from a single copy gene. Northern blotting performed with total RNA from various tissues of 6-week-old chickens revealed high levels of Ii-1 and Ii-2 mRNA expression in the spleen and bursa of Fabricius, and low levels of Ii-1 expression in the thymus, heart and liver, while Ii-2 was not expressed in these tissues. High levels of expression of both Ii isoforms were detected in the spleen and bursa of Fabricius during late embryogenesis. Immunofluorescence staining showed that Ii proteins were expressed in the cell membranes of the splenocytes. These data suggest that chicken Ii exists in two isoforms resulting from alternative splicing, and is strongly expressed in the major immune organs.
With a pair of degenerate primers, we further identified a duck invariant chain (Ii)) cDNA, named duck Ii-1, by RT-PCR and RACE. It was 1,190 bp in length and contained a 41 bp 5' untranslated region, a 669 bp open reading frame and a 480 bp 3' untranslated region. An alternative transcript encoding a thyroglobulin
利用一对自行设计的简并引物，通过RT-PCR和RACE方法，我们获得了鸭Ii链cDNA，并将其命名为鸭Ii-1。Ii-1长为1，190bp，含有一个41bp的5′不翻译区、一个669bp的开放阅读框和一个480bp的3′不翻译区。鸭Ii链也存在编码含有Tg区的异构体，我们将其命名为鸭Ii-2。鸭Ii-1与鸡Ii-1氨基酸序列的同源性为82％，与哺乳动物Ii P31／P33之间的同源性约为60％。鸭Ii-2 Tg区与鸡Ii-2Tg区在氨基酸水平上的相似性高达96％，与哺乳动物Ii链Tg区之间也达到70％。利用一对能同时扩增鸭Ii链两种异构体的引物，通过半定量RT-PCR检测不同组织Ii mRNA的分布情况，结果表明，Ii链两种异构体在不同组织中广泛表达，尤其在脾脏和法氏囊中高水平表达。应用comparative protein modeling分析了鸭Ii链三聚体区和Tg区的三维结构，它们与人Ii链相应domain的结构完全相似。这些结果表明鸭Ii链也存在两种异构体，它们主要在免疫器官中高表达，并且
The invariant chain (Ii) is a non-polymorphic type II transmembrane protein and plays a central role in regulating the expression and function of class II major histocompatibility complex (MHC) molecules. The biosynthesis of distinct forms of the invariant chain (Ii) protein from a unique gene as the result of differential splicing patterns has been observed in humans and mice. However, there have been no reports on the existence of Ii isoforms in avian species. In the present study, we identified two chicken Ii cDNAs by RT-PCR and RACE, and examined the Ii gene copy number, mRNA expression and protein expression by Southern blotting, Northern blotting and immunofluorescence confocal microscopy, respectively. One of the Ii cDNAs, named Ii-1, was 1,151 bp in length, and had an open reading frame (ORF) of 672 nucleotides, in agreement with a previously identified chicken Ii sequence; the other, named Ii-2, was 1,337 bp long and had an ORF of 861 nucleotides. The Ii-1 and Ii-2 isoforms are similar to each other where they overlap, and the sequence similarity between them is 99% at either the nucleotide or amino acid level. However, they differ in the presence or absence of a Tg domain. Southern blotting confirmed that these cDNAs were derived from a single copy gene. Northern blotting performed with total RNA from various tissues of 6-week-old chickens revealed high levels of Ii-1 and Ii-2 mRNA expression in the spleen and bursa of Fabricius, and low levels of Ii-1 expression in the thymus, heart and liver, while Ii-2 was not expressed in these tissues. High levels of expression of both Ii isoforms were detected in the spleen and bursa of Fabricius during late embryogenesis. Immunofluorescence staining showed that Ii proteins were expressed in the cell membranes of the splenocytes. These data suggest that chicken Ii exists in two isoforms resulting from alternative splicing, and is strongly expressed in the major immune organs.
With a pair of degenerate primers, we further identified a duck invariant chain (Ii)) cDNA, named duck Ii-1, by RT-PCR and RACE. It was 1,190 bp in length and contained a 41 bp 5' untranslated region, a 669 bp open reading frame and a 480 bp 3' untranslated region. An alternative transcript encoding a thyroglobulin
引文
1. Jones P, Murphy D, Hewgill D, Mcdevitt H. Detection of a common polypeptide chain in I-A and I-E sub-region immunoprecipitates. Immunochemistry 1978; 16:51-60.
2. Anderson M, Miller J. Invariant Chain Can Function as a Chaperone Protein for Class II Major Histocompatibility Complex Molecules. Proc Natl Acad Sci U S A 1992; 89:2282-2286.
3. Kropshofer H, Vogt A, Hammerling G Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition ofpeptide binding. Proc Natl Acad Sci U S A 1995; 92:8313-8317.
4. Serwe M, Reuter G, Sponaas A, Koch S, Koch N. Both invariant chain isoforms Ii31 and Ii41 promote class II antigen presentation. Int Immunol. 1997;9:983-991.
5. Bikoff E, Huang L, Episkopou V, van Meerwijk J, Germain R, Robertson E. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J ExpMed. 1993; 177:1699-1712.
6. Wright RJ, Bikoff EK, Stockinger B. The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice. Immunology 1998; 95:309-13.
7. Shachar I, Flavell R. Requirement for Invariant Chain in B Cell Maturation and Function. Science 1996; 274:106-108.
8. Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappa B-dependent transcription program.J Biol Chem 2001; 276:27203-27206.
9. Matza D, Lantner F, Bogoch Y, Flaishon L, Hershkoviz R, Shachar I. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proc Natl Acad Sci U S A 2002; 99:3018-3023.
10. Matza D, Kerem A, Medvedovsky H, Lantner F, Shachar I. Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain. Immunity 2002; 17:549-560.
11. Vigna J, Smith K, Lutz C. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove. J Immunol 1996;157:4503-4510.
12. Reber AJ, Turnquist HR, Thomas HJ, Lutz CT, Solheim JC. Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules. Immunogenetics 2002;54:74-81.
13. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004; 10:6606-11.
14. Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ. Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biol Ther 2004;3:1021-7.
15. Chamuleau ME, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, van de Loosdrecht AA, Ossenkoppele GJ. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 2004;64:5546-50.
16. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639-51.
17. Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol 2000;8:210-5.
18. Ansari AA. A possible role of the MHC-associated invariant chain in rheumatoid arthritis. Semin Arthritis Rheum 1993 ;23:193-7.
19. Hess AD, Thoburn C, Chen W, Miura Y, Van der Wall E. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self epitope from a tumor-associated antigen. Clin Immunol 2001; 101:67-76.
20. Van Tienhoven EA, ten Brink CT, van Bergen J, Koning F, van Eden W, Broeren CP. Induction of antigen specific CD4+ T cell responses by invariant chain based DNA vaccines. Vaccine 2001; 19:1515-9.
21. Fujii S, Senju S, Chen YZ, Ando M, Matsushita S, Nishimura Y. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum Immunol 1998;59:607-14.
22. Xu M, Lu X, Kallinteris NL, Wang Y, Wu S, von Hofe E, Gulfo JV, Humphreys RE, Hillman GG. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Curr Opin Mol Ther2004;6:160-5.
23. Levine F, Erlich HA, Mach B, Pious D. Transcriptional regulation of HLA class II and invariant chain genes. J Immunol 1985; 134:637-40.
24. Brown AM, Barr CL, Ting JP. Sequences homologous to class II MHC W, X, and Y elements mediate constitutive and IFN-gamma-induced expression of human class II-associated invariant chain gene. J Immunol 1991;146:3183-9.
25. Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochim Biophys Acta 2002;1542:l-13.
26. Genuardi M, Saunders G. Localization of the HLA class II -associated invariant chain gene to human chromosome band 5q32. Immunogenetics 1988;28:53-56.
27. Yamamoto K, Floyd-Smith G, Francke U, Koch N, Lauer W, Dobberstein B, Schafer R, Hammerling G. The gene encoding the la-associated invariant chain is located on chromosome 18 in the mouse. Immunogenetics 1985;21:83-90.
28. Strubin M, Berte C, Mach B. Alternative splicing and alternative initiation of translation explain the four forms of the Ia antigen-associated invariant chain. EMBO J 1986;5:3483-3488.
29. Fineschi B, Arneson L, Naujokas M, Miller J. Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41. Proc Natl Acad Sci U S A. 1995;92:10257-10261.
30. Bevec T, Stoka V, Pungercic G, Dolenc I, Turk V. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J Exp Med. 1996;183:1331-1338.
31. O'Sullivan DM, Noonan D, Quaranta V. Four Ia invariant chain forms derive from a single gene by alternate splicing and alternate initiation of transcription/translation. J Exp Med 1987; 166:444-60.
32. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990;63:707-16.
33. Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, Quaranta V, Peterson PA. Intracellular transport of class II. MHC molecules directed by invariant chain. Nature 1990;348:600-5.
34. Koch N, Harris AW. Differential expression of the invariant chain in mouse tumor cells: relationship to B lymphoid development. J Immunol 1984;132:12-5.
35. Koch N, Lauer W, Habicht J, Dobberstein B. Primary structure of the gene for the murine Ia antigen-associated invariant chains (Ii). An alternatively spliced exon encodes a cysteine-rich domain highly homologous to a repetitive sequence of thyroglobulin. Embo J 1987;6:1677-83.
36. Bijlmakers MJ, Benaroch P, Ploegh HL. Mapping functional regions in the lumenal domain of the class Il-associated invariant chain. J Exp Med 1994;180:623-9.
37. Gedde-Dahl M, Freisewinkel I, Staschewski M, Schenck K, Koch N, Bakke O. Exon 6 is essential for invariant chain trimerization and induction of large endosomal structures. J Biol Chem 1997;272:8281-7.
38. Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol 1997;9:89-96.
39. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-62.
40. Teyton L, O'Sullivan D, Dickson PW, Lotteau V, Sette A, Fink P, Peterson PA. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature 1990;348:39-44.
41. Bremnes B, Madsen T, Gedde-Dahl M, Bakke O. An LI and ML motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalization. J Cell Sci 1994;107 (Pt 7):2021-32.
42. Pieters J, Bakke O, Dobberstein B. The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail. J Cell Sci 1993;106(Pt3):831-46.
43. Odorizzi CG, Trowbridge IS, Xue L, Hopkins CR, Davis CD, Collawn JF. Sorting signals in the MHC class II invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment. J Cell Biol 1994; 126:317-30.
44. Jasanoff A, Wagner G, Wiley DC. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. Embo J 1998; 17:6812-8.
45. Jasanoff A, Park SJ, Wiley DC. Direct observation of disordered regions in the major histocompatibility complex class II-associated invariant chain. Proc Natl Acad Sci U S A 1995;92:9900-4.
46. Park SJ, Sadegh-Nasseri S, Wiley DC. Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1. Proc Natl Acad Sci U S A 1995;92:11289-93.
47. Anderson KS, Cresswell P. A role for calnexin (IP90) in the assembly of class II MHC molecules. Embo J 1994; 13:675-82.
48. Arunachalam B, Cresswell P. Molecular requirements for the interaction of class II major histocompatibility complex molecules and invariant chain with calnexin. J Biol Chem 1995;270:2784-90.
49. Bertolino P, Rabourdin-Combe C. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Crit Rev Immunol 1996;16:359-79.
50. Machamer CE, Cresswell P. Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens. J Immunol 1982; 129:2564-9.
51. Warmerdam PA, Long EO, Roche PA. Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartments. J Cell Biol 1996;133:281-91.
52. Roche PA, Teletski CL, Stang E, Bakke O, Long. EO. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci U S A 1993;90:8581-5.
53. Anderson MS, Swier K, Arneson L, Miller J. Enhanced antigen presentation in the absence of the invariant chain endosomal localization signal. J Exp Med 1993;178:1959-69.
54. Genuardi M, Saunders GF. Localization of the HLA class H-associated invariant chain gene to human chromosome band 5q32. Immunogenetics 1988;28:53-6.
55. Bangia N, Watts TH. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules. Int Immunol 1995;7:1585-91.
56. Kageyama T, Yonezawa S, Ichinose M, Miki K, Moriyama A. Potential sites for processing of the human invariant chain by cathepsins D and E. Biochem Biophys Res Commun 1996;223:549-53.
57. Morton PA, Zacheis ML, Giacoletto KS, Manning JA, Schwartz BD. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J Immunol 1995; 154:137-50.
58. Vogt AB, Stern LJ, Amshoff C, Dobberstein B, Hammerling GJ, Kropshofer H. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR. J Immunol 1995; 155:4757-65.
59. Stumptner P, Benaroch P. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region. Embo J 1997; 16:5807-18.
60. Lindstedt R, Liljedahl M, Peleraux A, Peterson PA, Karlsson L. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity 1995; 3:561-72.
61. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to MHC class II compartments. J Cell Biol 1995; 131:351-69.
62. Copier J, Kleijmeer MJ, Ponnambalam S, Oorschot V, Potter P, Trowsdale J, Kelly A. Targeting signal and subcellular compartments involved in the intracellular trafficking of HLA-DMB. J Immunol 1996;157:1017-27.
63. Fineschi B, Sakaguchi K. Appella E, Miller J. The proteolytic environment involved in MHC class Il-restricted antigen presentation can be modulated by the p41 form of invariant chain. J Immunol 1996; 157:3211-5.
64. Lennon-Dumenil AM, Roberts RA, Valentijn K, Driessen C, Overkleeft HS, Erickson A, Peters PJ, Bikoff E, Ploegh HL, Wolf Bryant P. The p41 isoform of invariant chain is a chaperone for cathepsin L. Embo J 2001;20:4055-64.
65. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, Villadangos JA, Ploegh H, Peters C, Rudensky AY. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998;280:450-3.
66. Zavasnik-Bergant V, Schweiger A, Bevec T, Golouh R, Turk V, Kos J. Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes. Immunology 2004;112:378-85.
67. Pierre P, Shachar I, Matza D, Gatti E, Flavell RA, Mellman I. Invariant chain controls H2-M proteolysis in mouse splenocytes and dendritic cells. Journal of Experimental Medicine 2000; 191:1057-1062.
68. Kenty G, Martin WD, Van Kaer L, Bikoff EK. MHC class II expression in double mutant mice lacking invariant chain and DM functions. J Immunol 1998; 160:606-14.
69. Rajagopalan G, Smart MK, Krco CJ, David CS. Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain. J Immunol 2002; 169:1774-83.
70. Kenty G, Bikoff EK. BALB c invariant chain mutant mice display relatively efficient maturation of CD4(+) T cells in the periphery and secondary proliferative responses elicited upon peptide challenge. Journal of Immunology 1999; 163:232-241.
71. Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends in Immunology 2003;24:264-268.
72. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 2000;100:391-8.
73. Wolfe MS, Kopan R. Intramembrane proteolysis: theme and variations. Science 2004;305:1119-23.
74. Maehr R, Kraus M, Ploegh HL. Mice deficient in invariant-chain and MHC class II exhibit a normal mature B2 cell compartment. Eur J Immunol 2004;34:2230-6.
75. Jayawardena-Wolf J, Benlagha K, Chiu YH, Mehr R, Bendelac A. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 2001; 15:897-908.
76. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
77. Neumann J, Eis-Hubinger AM, Koch N. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion. J Immunol 2003; 171:3075-83.
78. Schindler M, Wurfl S, Benaroch P, Greenough TC, Daniels R, Easterbrook P, Brenner M, Munch J, Kirchhoff F. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol 2003; 77:10548-56.
79. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999; 401:921-3.
80. Lader E, Clark BT, Jhanwar SC, Chaganti RS, Bennett D. Definitive chromosomal location of the H-2 complex by in situ hybridization to pachytene chromosomes. Immunogenetics 1985; 22:49-54.
81. Rahmsdorf HJ, Koch N, Mallick U, Herrlich P. Regulation of MHC class II invariant chain expression: induction of synthesis in human and murine plasmocytoma cells by arresting replication. Embo J 1983; 2:811-6.
82. Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochimica Et Biophysica Acta-Molecular Cell Research 2002; 1542:1-13.
83. Koch N, Wong GH, Schrader JW. Ia antigens and associated invariant chain are induced simultaneously in lines of T-dependent mast cells by recombinant interferon-gamma. J Immunol 1984;132:1361-9.
84. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, Ault KA, Gimbrone MA, Jr., Strominger JL, Pober JS. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci U S A 1984; 81:4917-21.
85. Boss JM. A common set of factors control the expression of the MHC class II, invariant chain, and HLA-DM genes. Microbes Infect 1999; 1:847-53.
86. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002;109 SuppI:S21-33.
87. Linhoff MW, Wright KL, Ting JP. CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Mol Cell Biol 1997;17:4589-96.
88. Wright KL, Moore TL, Vilen BJ, Brown AM, Ting JP. Major histocompatibility complex class II-associated invariant chain gene expression is up-regulated by cooperative interactions of Sp1 and NF-Y. J Biol Chem 1995; 270:20978-86.
89. Doyle C, Ford PJ, Ponath PD, Spies T, Strominger JL. Regulation of the class II-associated invariant chain gene in normal and mutant B lymphocytes. Proc Natl Acad Sci U S A 1990; 87:4590-4.
90. Brown AM, Linhoff MW, Stein B, Wright KL, Baldwin AS, Jr., Basta PV, Ting JP. Function of NF-kappa B/Rel binding sites in the major histocompatibility complex class II invariant chain promoter is dependent on cell-specific binding of different NF-kappa B/Rel subunits. Mol Cell Biol 1994; 14:2926-35.
91. Barr CL, Saunders GF. Interferon-gamma-inducible regulation of the human invariant chain gene. J Biol Chem 1991; 266:3475-81.
92. Pessara U, Koch N. Tumor necrosis factor alpha regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kappa B-like factor to a promoter element. Mol Cell Biol 1990; 10:4146-54.
93. Zhu L, Jones PP. Transcriptional control of the invariant chain gene involves promoter and enhancer elements common to and distinct from major histocompatibility complex class II genes. Mol Cell Biol 1990; 10:3906-16.
94. Hess AD, Thoburn C, Chen WR, Miura Y, Van der Wall E. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic 'self epitope from a tumor-associated antigen (vol 101, pg 67, 2001). Clinical Immunology 2001; 101:381-381.
95. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995; 92:11671-5.
96. Sanderson S, Frauwirth K, Shastri N. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci U S A 1995; 92:7217-21.
97. Bremnes B, Rode M, Gedde-Dahl M, Nordeng TW, Jacobsen J, Ness SA, Bakke O. The MHC class II-associated chicken invariant chain shares functional properties with its mammalian homologs. Exp Cell Res 2000; 259:360-369.
98. Nagata T, Aoshi T, Suzuki M, Uchijima M, Kim YH, Yang Z, Koide Y. Induction of protective immunity to Listeria monocytogenes by immunization with plasmid DNA expressing a helper T-cell epitope that replaces the class Il-associated invariant chain peptide of the invariant chain. Infect Immun 2002; 70:2676-80.
99. Nagata T, Higashi T, Aoshi T, Suzuki M, Uchijima M, Koide Y. Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain (Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization. Vaccine 2001; 20:105-14.
100. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class Il-associated invariant chain peptide. Cancer Res 2003; 63:5587-94.
101. Gregers TF, Fleckenstein B, Vartdal F, Roepstorff P, Bakke O, Sandlie I. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation. Int Immunol 2003;15:1291-9.
102. Van Bergen J, Schoenberger SP, Verreck F, Amons R, Offringa R, Koning F. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci U S A 1997; 94:7499-502.
103. Xu M, Jackson R, Adams S, Humphreys RE. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittelforschung 1999; 49:791-9.
104. Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E, Xu M. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000; 18:2693-7.
105. Kallinteris NL, Lu X, Wu S, Hu H, Li Y, Gulfo JV, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 2003;21:4128-32.
106. Kallinteris NL, Wu S, Lu X, von Hofe E, Humphreys RE, Xu M. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies. Vaccine 2005;23:2336-8.
107. Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 2004; 53:490-6.
108. Xu M, Li J, Gulfo JV, Von Hofe E, Humphreys RE. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 2001; 54:39-44.
109. Lu X, Kallinteris NL, Li J, Wu S, Li Y, Jiang Z, Hillman GG, Gulfo JV, Humphreys RE, Xu M. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol Immunother 2003; 52:592-8.
110.Wang Y, Xu M, Che M, Von Hofe E, Abbas A, Kallinteris NL, Lu X, Liss ZJ, Forman JD, Hillman GG. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein. Hum Gene Ther 2005; 16:187-99.
111. Hillman GG, Kallinteris NL, Li J, Wang Y, Lu X, Li Y, Wu S, Wright JL, Slos P, Gulfo JV, Humphreys RE, Xu M. Generating MHC Class Ⅱ+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class Ⅱ inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther 2003; 10:1512-8.
112. Yoder JA, Haire RN, Litman GW. Cloning of two zebrafish cDNAs that share domains with the MHC class Ⅱ-associated invariant chain. Immunogenetics 1999;50:84-88.
113. Dijkstra JM, Kiryu I, Kollner B, Yoshiura Y, Ototake M. MHC class Ⅱ invariant chain homologues in rainbow trout (Oncorhynehus mykiss). Fish & Shellfish Immunology 2003; 15:91-105.
114. Fujiki K, Smith CM, Liu L, Sundick RS, Dixon B. Alternate forms of MHC class Ⅱ-associated invariant chain are not produced by altemative splicing in rainbow trout (Oncorhynchus mykiss) but are encoded by separate genes. Dev Comp Immunol 2003;27:377-391.
115．王巧巧，张勇，杨裕国，袁勤，奚宏康，王福庆．自身免疫性甲状腺疾病中不变链的表达。中华内分泌代谢杂志，2000，16(6)：366-369．
116．郭荣，邹萍，范华骅，崔磊，曹谊林，郑滨，高跞，高峰，陆华中．CⅡTA反义cDNA抑制Hela细胞表面MHC Ⅱ类抗原的表达。中华血液学杂志．2003，24(12)：636-639．
117．白俊，任军，韩月恒，韩者忆，许彦鸣．HBsAg与恒定链融合基因真核表达载体的构建及鉴定。细胞与分子免疫学杂志．2004，20(6)：727-728．
118．高明，王海平，王燕宁，周勇，王全立．BALB／c小鼠I-A~dαB链和恒定链Ii在COS-7细胞中的共定位。军事医学科学院院刊．2004，6(28)：505-508
119. Jacob JP, Milne S, Beck S, Kaufman J. The major and a minor class Ⅱ beta-chain (B-LB) gene flank the Tapasin gene in the B-F/B-L region of the chicken major histocompatibility complex. Immunogenetics 2000;51:138-47.
120 Salomonsen J, Marston D, Avila D, Bumstead N, Johansson B, Juul-Madsen H, Olesen G, Riegert P, Skjodt K, Vainio O, Wiles M, Kaufman J. The properties of the single chicken MHC classical class Ⅱ a chain (B-LA) gene indicate an ancient origin for the DR/E-like isotype of class Ⅱ molecules. Immunogenetics 2003 ;55:605-614.
121．金伯泉主编．细胞和分子免疫学(第二版)．科学出版社，2001，page 315．
122. Veneziani B, Giallauria F, Gentile E "The disulfide bond pattern between fragments obtained by the limited proteolysis of bovine thyroglobulin." Biochimie 1999; 81: 517-525.
123. Kudo J, Chao LY, Narni F, Saunders GF. "Structure of the human gene encoding the invariant gamma-chain of class Ⅱ histocompatibility antigens." Nucleic Acids Res 1985; 13(24): 8827-41.
124. Albanesi C, Cavani A, Girolomoni G. "Interferon-gamma-stimulated human keratinoeytes express the genes necessary for the production of peptide-loaded MHC class Ⅱ molecules." J Invest Dermatol 1998; 110(2): 138-42.
125. Fineschi B, Arneson L, Naujokas M, Miller J. "Proteolysis of major histocompatibility complex class Ⅱ-associated invariant chain is regulated by the alternatively spliced gene product, p41." Proc Natl Acad Sci U S A. 1995; 92(22): 10257-10261.
126. Kampgen E, Koch N, Koch F, Stoger P, Heufler C, Schuler G, Romani N. "Class Ⅱ major histocompatibility complex molecules of murine dendritic cells: synthesis, sialylation of invariant chain, and antigen processing capacity are down-regulated upon culture." Proc Natl Acad Sci U S A 1991; 88(8): 3014-8.
127. Pure E, Inaba K, Crowley MT, Tardelli L, Witmer-Pack MD, Ruberti G, Fathman G, Steinman RM. "Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class Ⅱ molecules and expression ofinvariant chain." J Exp Med 1990; 172(5): 1459-69.
128．J．萨姆布鲁克，DW．拉塞尔等著(美)(黄培堂等译)2002．分子克隆实验指南(第三版)．北京：科学出版社。
129．郑作新编著1982．脊椎动物分类学．北京：农业出版社。
130. Bremnes B, Madsen T, Gedde-Dahl M, Bakke O. "An LI and ML motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalization." J Cell Sci 1994; 107 (Pt 7): 2021-32.
131. Odorizzi CG, Trowbridge IS, Xue L, Hopkins CR, Davis-CD, Collawn JF. "Sorting signals in the MHC class Ⅱ invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment." J Cell Biol 1994; 126(2): 317-30.
132. Pieters J, Bakke O, Dobberstein B. "The MHC class Ⅱ-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail." J Cell Sci 1993; 106 (Pt 3): 831-46.
133. Kang S, Liang L, Parker CD, Collawn JR "Structural requirements for major histocompatibility complex class Ⅱ invariant chain endocytosis and lysosomal targeting." J Biol Chem 1998; 273(32): 20644-52.
134. Pond L, Kuhn LA, Teyton L, Schutze MP, Tainer JA, Jackson MR, Peterson PA. "A role for acidic residues in di-leucine motif-based targeting to the endoeytic pathway." J Biol Chem 1995; 270(34): 19989-97.
135. Motta A, Bremnes B, Morelli MA, Frank RW, Saviano G, Bakke O. "Structure-activity relationship of the leueine-based sorting motifs in the eytosolie tail of the major histocompatibility complex-associated invariant chain." J Biol Chem 1995; 270(45): 27165-71.
136. Lipp J, Dobberstein B. "The membrane-spanning segment of invariant chain (I gamma) contains a potentially cleavable signal sequence." Cell 1986; 46(7): 1103-12.
137. Momburg F, Moller P. "Non-co-ordinate expression of HLA-DR antigens and invariant chain." Immunology 1988; 63(3): 551-3.
138. Badve S, Deshpande C, Hua Z, Logdberg L. "Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class Ⅱ antigens in the human fetus." J Histochem Cytochem 2002; 50(4): 473-82.
139．张铭湘，文剑，夏昆，郑多，张灼华，夏家辉．一种简便快速构建基因突变体的有效方法。中华医学遗传学杂志，2002，19(2)：145-147．
140. Becher-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated ietramembrane proteolysis (RIP) processed protein family. Mol Biol Cell. 2005 Aug 17; [Epub ahead of print]
141. Medina, M. and C.G. Dotti, RIPped out by presenilin-dependent gamma-secretase. Cell Signal, 2003.15(9): p. 829-41.
142. De Strooper, B., Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003 38(1): p. 9-12.
143. Duncan EA, Brown MS, Goldstein JL, Sakai J. Cleavage site for sterol-regulated protease localized to a Leu-Ser bond in the lumenal loop of sterol regulatory element-binding protein-2. J Biol Chem. 1997 272:12778-12785.
144. Urban S, Freeman M. Substrate specificity of rhomboid intramembrane proteases is governed by helix-breaking residues in the substrate transmembrane domain. Molecular cell. 2003 11: 1425-1434.
145．刘玉华硕士论文鸡Ii链基因的克隆、原核表达及其抗体制备(2005)
146. Jacob JP, Milne S, Beck S, Kaufman J. The major and a minor class Ⅱ beta-chain (B-LB) gene flank the Tapasin gene in the B-F/B-L region of the chicken major histocompatibility complex. Immunogenetics. 2000 51 (2): 138-47.
147. Salomonsen J, Marston D, Avila D, Bumstead N, Johansson B, Juul-Madsen H, Olesen G, Riegert P, Skjodt K, Vainio O, Wiles M, Kaufman J. The properties of the single chicken MHC classical class Ⅱ a chain (B-LA) gene indicate an ancient origin for the DR/E-like isotype of class Ⅱ molecules. Immunogenetics. 2003 55:605-614.
2. Anderson M, Miller J. Invariant Chain Can Function as a Chaperone Protein for Class II Major Histocompatibility Complex Molecules. Proc Natl Acad Sci U S A 1992; 89:2282-2286.
3. Kropshofer H, Vogt A, Hammerling G Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition ofpeptide binding. Proc Natl Acad Sci U S A 1995; 92:8313-8317.
4. Serwe M, Reuter G, Sponaas A, Koch S, Koch N. Both invariant chain isoforms Ii31 and Ii41 promote class II antigen presentation. Int Immunol. 1997;9:983-991.
5. Bikoff E, Huang L, Episkopou V, van Meerwijk J, Germain R, Robertson E. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J ExpMed. 1993; 177:1699-1712.
6. Wright RJ, Bikoff EK, Stockinger B. The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice. Immunology 1998; 95:309-13.
7. Shachar I, Flavell R. Requirement for Invariant Chain in B Cell Maturation and Function. Science 1996; 274:106-108.
8. Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappa B-dependent transcription program.J Biol Chem 2001; 276:27203-27206.
9. Matza D, Lantner F, Bogoch Y, Flaishon L, Hershkoviz R, Shachar I. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proc Natl Acad Sci U S A 2002; 99:3018-3023.
10. Matza D, Kerem A, Medvedovsky H, Lantner F, Shachar I. Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain. Immunity 2002; 17:549-560.
11. Vigna J, Smith K, Lutz C. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove. J Immunol 1996;157:4503-4510.
12. Reber AJ, Turnquist HR, Thomas HJ, Lutz CT, Solheim JC. Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules. Immunogenetics 2002;54:74-81.
13. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004; 10:6606-11.
14. Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ. Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biol Ther 2004;3:1021-7.
15. Chamuleau ME, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, van de Loosdrecht AA, Ossenkoppele GJ. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 2004;64:5546-50.
16. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639-51.
17. Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol 2000;8:210-5.
18. Ansari AA. A possible role of the MHC-associated invariant chain in rheumatoid arthritis. Semin Arthritis Rheum 1993 ;23:193-7.
19. Hess AD, Thoburn C, Chen W, Miura Y, Van der Wall E. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self epitope from a tumor-associated antigen. Clin Immunol 2001; 101:67-76.
20. Van Tienhoven EA, ten Brink CT, van Bergen J, Koning F, van Eden W, Broeren CP. Induction of antigen specific CD4+ T cell responses by invariant chain based DNA vaccines. Vaccine 2001; 19:1515-9.
21. Fujii S, Senju S, Chen YZ, Ando M, Matsushita S, Nishimura Y. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum Immunol 1998;59:607-14.
22. Xu M, Lu X, Kallinteris NL, Wang Y, Wu S, von Hofe E, Gulfo JV, Humphreys RE, Hillman GG. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Curr Opin Mol Ther2004;6:160-5.
23. Levine F, Erlich HA, Mach B, Pious D. Transcriptional regulation of HLA class II and invariant chain genes. J Immunol 1985; 134:637-40.
24. Brown AM, Barr CL, Ting JP. Sequences homologous to class II MHC W, X, and Y elements mediate constitutive and IFN-gamma-induced expression of human class II-associated invariant chain gene. J Immunol 1991;146:3183-9.
25. Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochim Biophys Acta 2002;1542:l-13.
26. Genuardi M, Saunders G. Localization of the HLA class II -associated invariant chain gene to human chromosome band 5q32. Immunogenetics 1988;28:53-56.
27. Yamamoto K, Floyd-Smith G, Francke U, Koch N, Lauer W, Dobberstein B, Schafer R, Hammerling G. The gene encoding the la-associated invariant chain is located on chromosome 18 in the mouse. Immunogenetics 1985;21:83-90.
28. Strubin M, Berte C, Mach B. Alternative splicing and alternative initiation of translation explain the four forms of the Ia antigen-associated invariant chain. EMBO J 1986;5:3483-3488.
29. Fineschi B, Arneson L, Naujokas M, Miller J. Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41. Proc Natl Acad Sci U S A. 1995;92:10257-10261.
30. Bevec T, Stoka V, Pungercic G, Dolenc I, Turk V. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J Exp Med. 1996;183:1331-1338.
31. O'Sullivan DM, Noonan D, Quaranta V. Four Ia invariant chain forms derive from a single gene by alternate splicing and alternate initiation of transcription/translation. J Exp Med 1987; 166:444-60.
32. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990;63:707-16.
33. Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, Quaranta V, Peterson PA. Intracellular transport of class II. MHC molecules directed by invariant chain. Nature 1990;348:600-5.
34. Koch N, Harris AW. Differential expression of the invariant chain in mouse tumor cells: relationship to B lymphoid development. J Immunol 1984;132:12-5.
35. Koch N, Lauer W, Habicht J, Dobberstein B. Primary structure of the gene for the murine Ia antigen-associated invariant chains (Ii). An alternatively spliced exon encodes a cysteine-rich domain highly homologous to a repetitive sequence of thyroglobulin. Embo J 1987;6:1677-83.
36. Bijlmakers MJ, Benaroch P, Ploegh HL. Mapping functional regions in the lumenal domain of the class Il-associated invariant chain. J Exp Med 1994;180:623-9.
37. Gedde-Dahl M, Freisewinkel I, Staschewski M, Schenck K, Koch N, Bakke O. Exon 6 is essential for invariant chain trimerization and induction of large endosomal structures. J Biol Chem 1997;272:8281-7.
38. Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol 1997;9:89-96.
39. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-62.
40. Teyton L, O'Sullivan D, Dickson PW, Lotteau V, Sette A, Fink P, Peterson PA. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature 1990;348:39-44.
41. Bremnes B, Madsen T, Gedde-Dahl M, Bakke O. An LI and ML motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalization. J Cell Sci 1994;107 (Pt 7):2021-32.
42. Pieters J, Bakke O, Dobberstein B. The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail. J Cell Sci 1993;106(Pt3):831-46.
43. Odorizzi CG, Trowbridge IS, Xue L, Hopkins CR, Davis CD, Collawn JF. Sorting signals in the MHC class II invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment. J Cell Biol 1994; 126:317-30.
44. Jasanoff A, Wagner G, Wiley DC. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. Embo J 1998; 17:6812-8.
45. Jasanoff A, Park SJ, Wiley DC. Direct observation of disordered regions in the major histocompatibility complex class II-associated invariant chain. Proc Natl Acad Sci U S A 1995;92:9900-4.
46. Park SJ, Sadegh-Nasseri S, Wiley DC. Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1. Proc Natl Acad Sci U S A 1995;92:11289-93.
47. Anderson KS, Cresswell P. A role for calnexin (IP90) in the assembly of class II MHC molecules. Embo J 1994; 13:675-82.
48. Arunachalam B, Cresswell P. Molecular requirements for the interaction of class II major histocompatibility complex molecules and invariant chain with calnexin. J Biol Chem 1995;270:2784-90.
49. Bertolino P, Rabourdin-Combe C. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Crit Rev Immunol 1996;16:359-79.
50. Machamer CE, Cresswell P. Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens. J Immunol 1982; 129:2564-9.
51. Warmerdam PA, Long EO, Roche PA. Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartments. J Cell Biol 1996;133:281-91.
52. Roche PA, Teletski CL, Stang E, Bakke O, Long. EO. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci U S A 1993;90:8581-5.
53. Anderson MS, Swier K, Arneson L, Miller J. Enhanced antigen presentation in the absence of the invariant chain endosomal localization signal. J Exp Med 1993;178:1959-69.
54. Genuardi M, Saunders GF. Localization of the HLA class H-associated invariant chain gene to human chromosome band 5q32. Immunogenetics 1988;28:53-6.
55. Bangia N, Watts TH. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules. Int Immunol 1995;7:1585-91.
56. Kageyama T, Yonezawa S, Ichinose M, Miki K, Moriyama A. Potential sites for processing of the human invariant chain by cathepsins D and E. Biochem Biophys Res Commun 1996;223:549-53.
57. Morton PA, Zacheis ML, Giacoletto KS, Manning JA, Schwartz BD. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J Immunol 1995; 154:137-50.
58. Vogt AB, Stern LJ, Amshoff C, Dobberstein B, Hammerling GJ, Kropshofer H. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR. J Immunol 1995; 155:4757-65.
59. Stumptner P, Benaroch P. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region. Embo J 1997; 16:5807-18.
60. Lindstedt R, Liljedahl M, Peleraux A, Peterson PA, Karlsson L. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity 1995; 3:561-72.
61. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to MHC class II compartments. J Cell Biol 1995; 131:351-69.
62. Copier J, Kleijmeer MJ, Ponnambalam S, Oorschot V, Potter P, Trowsdale J, Kelly A. Targeting signal and subcellular compartments involved in the intracellular trafficking of HLA-DMB. J Immunol 1996;157:1017-27.
63. Fineschi B, Sakaguchi K. Appella E, Miller J. The proteolytic environment involved in MHC class Il-restricted antigen presentation can be modulated by the p41 form of invariant chain. J Immunol 1996; 157:3211-5.
64. Lennon-Dumenil AM, Roberts RA, Valentijn K, Driessen C, Overkleeft HS, Erickson A, Peters PJ, Bikoff E, Ploegh HL, Wolf Bryant P. The p41 isoform of invariant chain is a chaperone for cathepsin L. Embo J 2001;20:4055-64.
65. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, Villadangos JA, Ploegh H, Peters C, Rudensky AY. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998;280:450-3.
66. Zavasnik-Bergant V, Schweiger A, Bevec T, Golouh R, Turk V, Kos J. Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes. Immunology 2004;112:378-85.
67. Pierre P, Shachar I, Matza D, Gatti E, Flavell RA, Mellman I. Invariant chain controls H2-M proteolysis in mouse splenocytes and dendritic cells. Journal of Experimental Medicine 2000; 191:1057-1062.
68. Kenty G, Martin WD, Van Kaer L, Bikoff EK. MHC class II expression in double mutant mice lacking invariant chain and DM functions. J Immunol 1998; 160:606-14.
69. Rajagopalan G, Smart MK, Krco CJ, David CS. Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain. J Immunol 2002; 169:1774-83.
70. Kenty G, Bikoff EK. BALB c invariant chain mutant mice display relatively efficient maturation of CD4(+) T cells in the periphery and secondary proliferative responses elicited upon peptide challenge. Journal of Immunology 1999; 163:232-241.
71. Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends in Immunology 2003;24:264-268.
72. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 2000;100:391-8.
73. Wolfe MS, Kopan R. Intramembrane proteolysis: theme and variations. Science 2004;305:1119-23.
74. Maehr R, Kraus M, Ploegh HL. Mice deficient in invariant-chain and MHC class II exhibit a normal mature B2 cell compartment. Eur J Immunol 2004;34:2230-6.
75. Jayawardena-Wolf J, Benlagha K, Chiu YH, Mehr R, Bendelac A. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 2001; 15:897-908.
76. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
77. Neumann J, Eis-Hubinger AM, Koch N. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion. J Immunol 2003; 171:3075-83.
78. Schindler M, Wurfl S, Benaroch P, Greenough TC, Daniels R, Easterbrook P, Brenner M, Munch J, Kirchhoff F. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol 2003; 77:10548-56.
79. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999; 401:921-3.
80. Lader E, Clark BT, Jhanwar SC, Chaganti RS, Bennett D. Definitive chromosomal location of the H-2 complex by in situ hybridization to pachytene chromosomes. Immunogenetics 1985; 22:49-54.
81. Rahmsdorf HJ, Koch N, Mallick U, Herrlich P. Regulation of MHC class II invariant chain expression: induction of synthesis in human and murine plasmocytoma cells by arresting replication. Embo J 1983; 2:811-6.
82. Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochimica Et Biophysica Acta-Molecular Cell Research 2002; 1542:1-13.
83. Koch N, Wong GH, Schrader JW. Ia antigens and associated invariant chain are induced simultaneously in lines of T-dependent mast cells by recombinant interferon-gamma. J Immunol 1984;132:1361-9.
84. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, Ault KA, Gimbrone MA, Jr., Strominger JL, Pober JS. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci U S A 1984; 81:4917-21.
85. Boss JM. A common set of factors control the expression of the MHC class II, invariant chain, and HLA-DM genes. Microbes Infect 1999; 1:847-53.
86. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002;109 SuppI:S21-33.
87. Linhoff MW, Wright KL, Ting JP. CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Mol Cell Biol 1997;17:4589-96.
88. Wright KL, Moore TL, Vilen BJ, Brown AM, Ting JP. Major histocompatibility complex class II-associated invariant chain gene expression is up-regulated by cooperative interactions of Sp1 and NF-Y. J Biol Chem 1995; 270:20978-86.
89. Doyle C, Ford PJ, Ponath PD, Spies T, Strominger JL. Regulation of the class II-associated invariant chain gene in normal and mutant B lymphocytes. Proc Natl Acad Sci U S A 1990; 87:4590-4.
90. Brown AM, Linhoff MW, Stein B, Wright KL, Baldwin AS, Jr., Basta PV, Ting JP. Function of NF-kappa B/Rel binding sites in the major histocompatibility complex class II invariant chain promoter is dependent on cell-specific binding of different NF-kappa B/Rel subunits. Mol Cell Biol 1994; 14:2926-35.
91. Barr CL, Saunders GF. Interferon-gamma-inducible regulation of the human invariant chain gene. J Biol Chem 1991; 266:3475-81.
92. Pessara U, Koch N. Tumor necrosis factor alpha regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kappa B-like factor to a promoter element. Mol Cell Biol 1990; 10:4146-54.
93. Zhu L, Jones PP. Transcriptional control of the invariant chain gene involves promoter and enhancer elements common to and distinct from major histocompatibility complex class II genes. Mol Cell Biol 1990; 10:3906-16.
94. Hess AD, Thoburn C, Chen WR, Miura Y, Van der Wall E. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic 'self epitope from a tumor-associated antigen (vol 101, pg 67, 2001). Clinical Immunology 2001; 101:381-381.
95. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995; 92:11671-5.
96. Sanderson S, Frauwirth K, Shastri N. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci U S A 1995; 92:7217-21.
97. Bremnes B, Rode M, Gedde-Dahl M, Nordeng TW, Jacobsen J, Ness SA, Bakke O. The MHC class II-associated chicken invariant chain shares functional properties with its mammalian homologs. Exp Cell Res 2000; 259:360-369.
98. Nagata T, Aoshi T, Suzuki M, Uchijima M, Kim YH, Yang Z, Koide Y. Induction of protective immunity to Listeria monocytogenes by immunization with plasmid DNA expressing a helper T-cell epitope that replaces the class Il-associated invariant chain peptide of the invariant chain. Infect Immun 2002; 70:2676-80.
99. Nagata T, Higashi T, Aoshi T, Suzuki M, Uchijima M, Koide Y. Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain (Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization. Vaccine 2001; 20:105-14.
100. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class Il-associated invariant chain peptide. Cancer Res 2003; 63:5587-94.
101. Gregers TF, Fleckenstein B, Vartdal F, Roepstorff P, Bakke O, Sandlie I. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation. Int Immunol 2003;15:1291-9.
102. Van Bergen J, Schoenberger SP, Verreck F, Amons R, Offringa R, Koning F. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci U S A 1997; 94:7499-502.
103. Xu M, Jackson R, Adams S, Humphreys RE. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittelforschung 1999; 49:791-9.
104. Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E, Xu M. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000; 18:2693-7.
105. Kallinteris NL, Lu X, Wu S, Hu H, Li Y, Gulfo JV, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 2003;21:4128-32.
106. Kallinteris NL, Wu S, Lu X, von Hofe E, Humphreys RE, Xu M. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies. Vaccine 2005;23:2336-8.
107. Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 2004; 53:490-6.
108. Xu M, Li J, Gulfo JV, Von Hofe E, Humphreys RE. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 2001; 54:39-44.
109. Lu X, Kallinteris NL, Li J, Wu S, Li Y, Jiang Z, Hillman GG, Gulfo JV, Humphreys RE, Xu M. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol Immunother 2003; 52:592-8.
110.Wang Y, Xu M, Che M, Von Hofe E, Abbas A, Kallinteris NL, Lu X, Liss ZJ, Forman JD, Hillman GG. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein. Hum Gene Ther 2005; 16:187-99.
111. Hillman GG, Kallinteris NL, Li J, Wang Y, Lu X, Li Y, Wu S, Wright JL, Slos P, Gulfo JV, Humphreys RE, Xu M. Generating MHC Class Ⅱ+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class Ⅱ inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther 2003; 10:1512-8.
112. Yoder JA, Haire RN, Litman GW. Cloning of two zebrafish cDNAs that share domains with the MHC class Ⅱ-associated invariant chain. Immunogenetics 1999;50:84-88.
113. Dijkstra JM, Kiryu I, Kollner B, Yoshiura Y, Ototake M. MHC class Ⅱ invariant chain homologues in rainbow trout (Oncorhynehus mykiss). Fish & Shellfish Immunology 2003; 15:91-105.
114. Fujiki K, Smith CM, Liu L, Sundick RS, Dixon B. Alternate forms of MHC class Ⅱ-associated invariant chain are not produced by altemative splicing in rainbow trout (Oncorhynchus mykiss) but are encoded by separate genes. Dev Comp Immunol 2003;27:377-391.
115．王巧巧，张勇，杨裕国，袁勤，奚宏康，王福庆．自身免疫性甲状腺疾病中不变链的表达。中华内分泌代谢杂志，2000，16(6)：366-369．
116．郭荣，邹萍，范华骅，崔磊，曹谊林，郑滨，高跞，高峰，陆华中．CⅡTA反义cDNA抑制Hela细胞表面MHC Ⅱ类抗原的表达。中华血液学杂志．2003，24(12)：636-639．
117．白俊，任军，韩月恒，韩者忆，许彦鸣．HBsAg与恒定链融合基因真核表达载体的构建及鉴定。细胞与分子免疫学杂志．2004，20(6)：727-728．
118．高明，王海平，王燕宁，周勇，王全立．BALB／c小鼠I-A~dαB链和恒定链Ii在COS-7细胞中的共定位。军事医学科学院院刊．2004，6(28)：505-508
119. Jacob JP, Milne S, Beck S, Kaufman J. The major and a minor class Ⅱ beta-chain (B-LB) gene flank the Tapasin gene in the B-F/B-L region of the chicken major histocompatibility complex. Immunogenetics 2000;51:138-47.
120 Salomonsen J, Marston D, Avila D, Bumstead N, Johansson B, Juul-Madsen H, Olesen G, Riegert P, Skjodt K, Vainio O, Wiles M, Kaufman J. The properties of the single chicken MHC classical class Ⅱ a chain (B-LA) gene indicate an ancient origin for the DR/E-like isotype of class Ⅱ molecules. Immunogenetics 2003 ;55:605-614.
121．金伯泉主编．细胞和分子免疫学(第二版)．科学出版社，2001，page 315．
122. Veneziani B, Giallauria F, Gentile E "The disulfide bond pattern between fragments obtained by the limited proteolysis of bovine thyroglobulin." Biochimie 1999; 81: 517-525.
123. Kudo J, Chao LY, Narni F, Saunders GF. "Structure of the human gene encoding the invariant gamma-chain of class Ⅱ histocompatibility antigens." Nucleic Acids Res 1985; 13(24): 8827-41.
124. Albanesi C, Cavani A, Girolomoni G. "Interferon-gamma-stimulated human keratinoeytes express the genes necessary for the production of peptide-loaded MHC class Ⅱ molecules." J Invest Dermatol 1998; 110(2): 138-42.
125. Fineschi B, Arneson L, Naujokas M, Miller J. "Proteolysis of major histocompatibility complex class Ⅱ-associated invariant chain is regulated by the alternatively spliced gene product, p41." Proc Natl Acad Sci U S A. 1995; 92(22): 10257-10261.
126. Kampgen E, Koch N, Koch F, Stoger P, Heufler C, Schuler G, Romani N. "Class Ⅱ major histocompatibility complex molecules of murine dendritic cells: synthesis, sialylation of invariant chain, and antigen processing capacity are down-regulated upon culture." Proc Natl Acad Sci U S A 1991; 88(8): 3014-8.
127. Pure E, Inaba K, Crowley MT, Tardelli L, Witmer-Pack MD, Ruberti G, Fathman G, Steinman RM. "Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class Ⅱ molecules and expression ofinvariant chain." J Exp Med 1990; 172(5): 1459-69.
128．J．萨姆布鲁克，DW．拉塞尔等著(美)(黄培堂等译)2002．分子克隆实验指南(第三版)．北京：科学出版社。
129．郑作新编著1982．脊椎动物分类学．北京：农业出版社。
130. Bremnes B, Madsen T, Gedde-Dahl M, Bakke O. "An LI and ML motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalization." J Cell Sci 1994; 107 (Pt 7): 2021-32.
131. Odorizzi CG, Trowbridge IS, Xue L, Hopkins CR, Davis-CD, Collawn JF. "Sorting signals in the MHC class Ⅱ invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment." J Cell Biol 1994; 126(2): 317-30.
132. Pieters J, Bakke O, Dobberstein B. "The MHC class Ⅱ-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail." J Cell Sci 1993; 106 (Pt 3): 831-46.
133. Kang S, Liang L, Parker CD, Collawn JR "Structural requirements for major histocompatibility complex class Ⅱ invariant chain endocytosis and lysosomal targeting." J Biol Chem 1998; 273(32): 20644-52.
134. Pond L, Kuhn LA, Teyton L, Schutze MP, Tainer JA, Jackson MR, Peterson PA. "A role for acidic residues in di-leucine motif-based targeting to the endoeytic pathway." J Biol Chem 1995; 270(34): 19989-97.
135. Motta A, Bremnes B, Morelli MA, Frank RW, Saviano G, Bakke O. "Structure-activity relationship of the leueine-based sorting motifs in the eytosolie tail of the major histocompatibility complex-associated invariant chain." J Biol Chem 1995; 270(45): 27165-71.
136. Lipp J, Dobberstein B. "The membrane-spanning segment of invariant chain (I gamma) contains a potentially cleavable signal sequence." Cell 1986; 46(7): 1103-12.
137. Momburg F, Moller P. "Non-co-ordinate expression of HLA-DR antigens and invariant chain." Immunology 1988; 63(3): 551-3.
138. Badve S, Deshpande C, Hua Z, Logdberg L. "Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class Ⅱ antigens in the human fetus." J Histochem Cytochem 2002; 50(4): 473-82.
139．张铭湘，文剑，夏昆，郑多，张灼华，夏家辉．一种简便快速构建基因突变体的有效方法。中华医学遗传学杂志，2002，19(2)：145-147．
140. Becher-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated ietramembrane proteolysis (RIP) processed protein family. Mol Biol Cell. 2005 Aug 17; [Epub ahead of print]
141. Medina, M. and C.G. Dotti, RIPped out by presenilin-dependent gamma-secretase. Cell Signal, 2003.15(9): p. 829-41.
142. De Strooper, B., Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003 38(1): p. 9-12.
143. Duncan EA, Brown MS, Goldstein JL, Sakai J. Cleavage site for sterol-regulated protease localized to a Leu-Ser bond in the lumenal loop of sterol regulatory element-binding protein-2. J Biol Chem. 1997 272:12778-12785.
144. Urban S, Freeman M. Substrate specificity of rhomboid intramembrane proteases is governed by helix-breaking residues in the substrate transmembrane domain. Molecular cell. 2003 11: 1425-1434.
145．刘玉华硕士论文鸡Ii链基因的克隆、原核表达及其抗体制备(2005)
146. Jacob JP, Milne S, Beck S, Kaufman J. The major and a minor class Ⅱ beta-chain (B-LB) gene flank the Tapasin gene in the B-F/B-L region of the chicken major histocompatibility complex. Immunogenetics. 2000 51 (2): 138-47.
147. Salomonsen J, Marston D, Avila D, Bumstead N, Johansson B, Juul-Madsen H, Olesen G, Riegert P, Skjodt K, Vainio O, Wiles M, Kaufman J. The properties of the single chicken MHC classical class Ⅱ a chain (B-LA) gene indicate an ancient origin for the DR/E-like isotype of class Ⅱ molecules. Immunogenetics. 2003 55:605-614.